 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Incyte
INCY
conference date: April 30, 2024 @ 5:00 AM Pacific Time
Incyte FDA Approvals To Propel Future Growth [Seeking Alpha, September 18, 2020]
Incyte A Buy On 2020 Guidance And Possible Drug Approvals [Seeking Alpha, February 19, 2020]
Incyte: A Buy On Revenue, EPS Growth And Strong Pipeline [Seeking Alpha, November 15, 2019]
2024 |
|||
| Incyte Q4 2023 |
Incyte Q1 2024 |
||
| Feb. 13, 2024 | Apr. 30, 2024 | ||
2023 |
|||
| Incyte Q4 2022 |
Incyte Q1 2023 |
Incyte Q2 2023 |
Incyte Q3 2023 |
| Feb. 7, 2023 | May 2, 2023 | Aug. 1, 2023 | Oct. 31, 2023 |
2022 |
|||
| Incyte Q4 2021 |
Incyte Q1 2022 |
Incyte Q2 2022 |
Incyte Q3 2022 |
| Feb. 8, 2022 | May 3, 2022 | August 2, 2022 | Nov. 1, 2022 |
2021 |
|||
| Incyte Q4 2020 |
Incyte Q1 2021 |
Incyte Q2 2021 |
Incyte Q3 2021 |
| Feb. 9, 2021 | May 4, 2021 | Aug. 3, 2021 | Nov. 2, 2021 |
2020 |
|||
| Incyte Q4 2019 |
Incyte Q1 2020 |
Incyte Q2 2020 |
Incyte Q3 2020 |
| Feb. 13, 2020 | May 5, 2020 | Aug. 4, 2020 | Nov. 5, 2020 |
2019 |
|||
| Incyte Q4 2018 |
Incyte Q1 2019 |
Incyte Q2 2019 |
Incyte Q3 2019 |
| Feb. 14, 2019 | April 30, 2019 | July 30, 2019 | Oct. 29, 2019 |
2018 |
|||
Feb. 15, 2018 |
May 11, 2018 |
July 31, 2018 |
Oct. 30, 2018 |
2017 |
|||
Feb. 14, 2017 |
May 4, 2017 |
August 1, 2017 |
Oct. 31, 2017 |
2016 |
|||
02/11/2016 |
05/09/2016 |
08/09/2016 |
11/01/2016 |
Incyte Should Break Out Of Doldrums by William Meyers [Seeking Alpha, August 28, 2018]
Incyte Q3 Result Could Be An Upward Inflection Point [Seeking Alpha, 11/2/2017]
Pharmacyclics, BioMarin, And Incyte: A Quick Screen [Seeking Alpha, 3/26/2015]
Incyte (INCY) is a commercial-stage biotechnology company specializing in targetted cancer therapies and immunotherapies.
I sold my small position in Q4 2023
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BLRX |
| BLUE |
| BMY |
| CLDX |
| CDTX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| IMGN |
| INO |
| IONS |
| MCHP |
| PLX |
| REGN |
| RNA |
| SAGE |
| SANA |
| SGEN |
| TSVT |
| VRTX |
| VSTM |
| WBA |
Disclaimer: My analyst summaries may include both my condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2024 William P. Meyers